Navigation Links
Amgen Announces 2011 Fourth Quarter Dividend
Date:10/13/2011

THOUSAND OAKS, Calif., Oct. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.28 per share dividend for the fourth quarter of 2011. The dividend will be paid on Dec. 8, 2011 to all stockholders of record as of the close of business on Nov. 17, 2011.  

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2010, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amgen to Present at the UBS Global Life Sciences Conference
2. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
3. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
4. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
5. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
6. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
7. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
8. Amgen Statement on CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
9. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
10. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
11. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... May 24, 2013 Many factors impact ... uptake or efflux transporters at the blood-tissue barrier. Even ... to unbound fractions in the tissue rather than the ... disposition challenges is required to guide lead optimization, predict ... any species-dependent variables that may impact the likely human ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... 19 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... II study with intramuscular (i.m.) injection of ... of seasonal and,life-threatening influenza. (Logo: ... a randomized, double-blind, placebo-controlled clinical,trial designed to ...
... 19 Health and Human,Services Secretary Mike ... the goal of personalized health care and ... and health care delivery should be,aligned to ... time" for each,individual patient., The report, ...
... Life,Sciences, Inc. (Nasdaq: CALP ) today announced that ... New York City will be webcast on,Tuesday, September 25 ... Caliper, will be providing an update on the company,s ... http://www.caliperls.com and clicking on the,link for the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7HHS Issues First Department-Wide Report on Personalized Health Care 2HHS Issues First Department-Wide Report on Personalized Health Care 3
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... release is available in Spanish . , Adolescents ... condition and regular physical activity present increased levels of insulin ... diabetes, appetite control and energy expenditure. This was the conclusion ... Physiology of the University of Granada . Further, after ...
... increasingly common and effective for operating inside the human ... tools inserted into the body of the patient, the ... determining the success of the operation. A team of ... a $2.3 million federal grant to develop a touch-sensitive ...
... next generation sequencing (NGS) and Certified Service Provider for ... a leading company in complex analysis and interpretation of ... complete human exome array, based on Roche NimbleGen sequence ... comprehensive service for human exome capture, targeted re-sequencing and ...
Cached Biology News:Children in good shape have better appetite control and energy expenditure 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 3Eurofins MWG Operon and Genomatix developed most complete human exome array 2
...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
Biology Products: